<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063189</url>
  </required_header>
  <id_info>
    <org_study_id>BiRd 2017-288-1</org_study_id>
    <nct_id>NCT04063189</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma</brief_title>
  <official_title>A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      BiRd regimen consisting of clarithromycin and Rd is safe and effective in NDMM. It can
      significantly increase ORR (up to 90.3%) , relief depth (≥VGPR), and prolong PFS to 43
      months. In our previous study, thirty RRMM patients treated with BiRd regimen in 6 centers in
      China benefited.It suggested that BiRd regimen may not only improve overall efficacy of RRMM
      , especially long-term benefits, but also reverse Rd resistance in patients who fail to
      achieve any remission after multiline therapy.The study is a Prospective, Multicenter, Single
      Arm, Phase II Clinical Trial, which intend to recruit first relapse MM patients over 18 years
      old. Once included, patients will receive the treatment of Clarithromycin Lenalidomide
      Dexamethasone (BiRd) Regimen. (Clarithromycin 500mg，po，bid，d1-21; Lenalidomide
      25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone
      20mg，po，daily，d1-2, 8-9,15-16, 22-23) And we will evaluate efficacy and adverse events of the
      BiRd regimen at a point of time predetermined.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Every 2 months until disease progression or study completion，an average of 2 year</time_frame>
    <description>According to the criteria of IMWG 2016</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v4.03</measure>
    <time_frame>Through study completion,an average of 2 year</time_frame>
    <description>According to NCI-CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>PFS were calculated from the enrollment to the first instance of disease progression, relapse, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>OS were calculated from the time of enrollment to death or the last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>the time from the first assessment of CR (complete response) or PR (partial response) to the first PD (Progressive Disease) or any cause of death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health-Related Quality of Life (HRQoL)</measure>
    <time_frame>Every 6 months until disease progression or study completion，an average of 2 year</time_frame>
    <description>According to the data of SF-36 Quality of Life Questionnaire Survey</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <arm_group>
    <arm_group_label>First Relapsed Multiple Myeloma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen</intervention_name>
    <description>Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23</description>
    <arm_group_label>First Relapsed Multiple Myeloma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosed as symptomatic multiple myeloma.

          2. the first relapse/progression with thalidomide, bortezomib or lenalidomide based
             current first-line treatment or resistance to the first-line treatment (previous
             treatment line number =1).

          3. there must be measurable lesions to determine disease progression (PD): according to
             the IMWG 2016 efficacy evaluation criteria.

          4. the expected survival time is longer than 3 months.

          5. ECOG score less than 2 points.

          6. the serum AST/ALT level ＜3 times higher than the normal value; the serum total
             bilirubin level＜2 times of the normal value; creatinine clearance rate was ≥30ml/mi.

          7. neutrophil count ＞1000/mm3 ; platelet count &gt;75000/mm3 (if bone marrow plasma cell
             &lt;50%) or &gt;30000/mm3 (if the plasma cells in the bone marrow is not less than 50%).

          8. women of childbearing age were negative for pregnancy before admission, and agreed to
             carry out pregnancy screening during the study (once a month until 4 weeks after the
             last dose), and agreed to use contraceptive measures within 3 months after the study
             and the last dose.

          9. all patients were required to sign informed consent.

        Exclusion Criteria:

          1. under the age of 18

          2. ECOG score &gt;2

          3. non secretory myeloma, defined as serum protein M &lt; 1g/dL, urinary M protein &lt;
             200mg/24h and sFLCR ≤100mg/L

          4. there is growing demand, pregnant or lactating women within one year

          5. HIV infection

          6. activity of HBV or HCV infection

          7. 4 weeks before entering the group of thromboembolic events

          8. not signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengyan Jin, professor</last_name>
    <role>Study Director</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fengyan Jin, professor</last_name>
    <phone>13844989638</phone>
    <email>fengyanjin@jlu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengyan Jin, Professor</last_name>
      <phone>+8613844989638</phone>
      <email>fengyanjin@jlu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011 Mar 17;364(11):1046-60. doi: 10.1056/NEJMra1011442. Review.</citation>
    <PMID>21410373</PMID>
  </reference>
  <reference>
    <citation>Agarwal A, Chow E, Bhutani M, Voorhees PM, Friend R, Usmani SZ. Practical Considerations in Managing Relapsed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):69-77. doi: 10.1016/j.clml.2016.11.010. Epub 2016 Nov 23. Review.</citation>
    <PMID>27986429</PMID>
  </reference>
  <reference>
    <citation>Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.</citation>
    <PMID>27531679</PMID>
  </reference>
  <reference>
    <citation>Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.</citation>
    <PMID>27843120</PMID>
  </reference>
  <reference>
    <citation>Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42.</citation>
    <PMID>18032763</PMID>
  </reference>
  <reference>
    <citation>Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. Erratum in: N Engl J Med. 2009 Jul 30;361(5):544.</citation>
    <PMID>18032762</PMID>
  </reference>
  <reference>
    <citation>Hou J, Du X, Jin J, Cai Z, Chen F, Zhou DB, Yu L, Ke X, Li X, Wu D, Meng F, Ai H, Zhang J, Wortman-Vayn H, Chen N, Mei J, Wang J. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. J Hematol Oncol. 2013 Jun 19;6:41. doi: 10.1186/1756-8722-6-41.</citation>
    <PMID>23782711</PMID>
  </reference>
  <reference>
    <citation>Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. doi: 10.1038/leu.2009.147. Epub 2009 Jul 23.</citation>
    <PMID>19626046</PMID>
  </reference>
  <reference>
    <citation>Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013 Mar 14;121(11):1982-5. doi: 10.1182/blood-2012-08-448563. Epub 2013 Jan 8.</citation>
    <PMID>23299315</PMID>
  </reference>
  <reference>
    <citation>Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008 Feb 1;111(3):1101-9. Epub 2007 Nov 7.</citation>
    <PMID>17989313</PMID>
  </reference>
  <reference>
    <citation>Kato H, Onishi Y, Okitsu Y, Katsuoka Y, Fujiwara T, Fukuhara N, Ishizawa K, Takagawa M, Harigae H. Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide. Ann Hematol. 2013 Dec;92(12):1711-2. doi: 10.1007/s00277-013-1761-x. Epub 2013 Apr 28.</citation>
    <PMID>23625297</PMID>
  </reference>
  <reference>
    <citation>Ghosh N, Tucker N, Zahurak M, Wozney J, Borrello I, Huff CA. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. Am J Hematol. 2014 Aug;89(8):E116-20. doi: 10.1002/ajh.23733. Epub 2014 Apr 26.</citation>
    <PMID>24723438</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>August 17, 2019</last_update_submitted>
  <last_update_submitted_qc>August 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>FengYan Jin</investigator_full_name>
    <investigator_title>MD, PHD, Physician in Charge of Hematology Department</investigator_title>
  </responsible_party>
  <keyword>Clarithromycin Lenalidomide Dexamethasone Regimen</keyword>
  <keyword>Treatment Response</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

